Actively Recruiting
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
Led by Centre Oscar Lambret · Updated on 2026-03-18
377
Participants Needed
11
Research Sites
304 weeks
Total Duration
On this page
Sponsors
C
Centre Oscar Lambret
Lead Sponsor
C
Canceropôle Nord Ouest
Collaborating Sponsor
AI-Summary
What this Trial Is About
ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment. Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone. All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.
CONDITIONS
Official Title
Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatment.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of soft tissue or visceral sarcoma
- Inoperable metastatic or locally advanced disease
- Planned systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide, or dacarbazine monotherapy
- Covered by French social security
- Provided written, signed informed consent
You will not qualify if you...
- Previous participation in the ePPS trial for a prior systemic treatment
- Poor understanding of French language
- Difficulty accessing a computer
- Pregnant or nursing women
- Persons deprived of liberty or under guardianship
- Unable to undergo medical follow-up due to geographical, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France, 69373
Actively Recruiting
2
CHU Jean Minjoz
Besançon, Bourgogne-Franche-Comté, France, 25000
Actively Recruiting
3
Centre Eugène Marquis
Rennes, Brittany Region, France, 35042
Not Yet Recruiting
4
Centre Paul Strauss
Strasbourg, Grand Est, France, 67033
Actively Recruiting
5
Centre Oscar Lambret
Lille, Hauts-de-France, France, 59020
Actively Recruiting
6
CHU de Poitiers
Poitiers, New Aquitaine, France, 86021
Actively Recruiting
7
Institut Claudius Regaud
Toulouse, Occitanie, France, 31059
Withdrawn
8
Institut de Cancérologie de l'Ouest
Saint-Herblain, Pays de la Loire Region, France, 44805
Actively Recruiting
9
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France, 54519
Not Yet Recruiting
10
Hôpital Pitié-Salpêtrière AP-HP
Paris, Île-de-France Region, France, 75013
Not Yet Recruiting
11
Gustave Roussy
Villejuif, Île-de-France Region, France, 94800
Actively Recruiting
Research Team
P
PANNIER Diane, DR
CONTACT
T
THERY Julien, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here